Evidence map›Paper›PMID 38730268›Full record

ArticleNature communications2024

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom and 19 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Filipa Lynce *Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-6615-7076
Candace Mainor *MedStar Georgetown University Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0002-4431-7101
Renee N Donahue *Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6828-3073
Xue GengGeorgetown University, Washington, DC, USA.ORCID http://orcid.org/0000-0003-4100-9899
Greg JonesNeoGenomics, Durham, NC, USA.ORCID http://orcid.org/0000-0001-9652-0294
Ilana SchlamMedStar Washington Hospital Center, Washington, DC, USA.ORCID http://orcid.org/0000-0003-4996-0400
Hongkun WangGeorgetown University, Washington, DC, USA.
Nicole J ToneyCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Caroline JochemsCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-9000-9855
Jeffrey SchlomCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-7932-4072
Jay ZeckMedStar Georgetown University Hospital, Washington, DC, USA.ORCID http://orcid.org/0009-0007-8847-7223
Christopher GallagherMedStar Washington Hospital Center, Washington, DC, USA.ORCID http://orcid.org/0000-0002-3846-5052
Rita NandaUniversity of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-5248-0876
Deena GrahamHackensack University Medical Center, Hackensack, NJ, USA.ORCID http://orcid.org/0000-0003-1111-6984
Erica M Stringer-ReasorUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Neelima DenduluriAstraZeneca, Arlington, VA, USA.ORCID http://orcid.org/0000-0002-6075-6809
Julie CollinsMedStar Georgetown University Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0001-5702-4693
Ami ChitaliaMedStar Washington Hospital Center, Washington, DC, USA.ORCID http://orcid.org/0009-0001-0274-2150
Shruti TiwariMedStar Washington Hospital Center, Washington, DC, USA.
Raquel NunesJohns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0552-1644
Rebecca KaltmanInova, Fairfax, VA, USA.
Katia KhouryUniversity of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0003-3899-8649
Margaret Gatti-MaysThe Ohio State University, Columbus, OH, USA.
Paolo TarantinoDivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8686-0228
Sara M TolaneyDivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5940-8671
Sandra M SwainGeorgetown University, Washington, DC, USA.ORCID http://orcid.org/0000-0002-1320-3830
Paula PohlmannMedStar Georgetown University Hospital, Washington, DC, USA.
Heather A ParsonsDivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8178-6612
Claudine IsaacsGeorgetown University, Washington, DC, USA.ORCID http://orcid.org/0000-0002-9646-1260

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38730268
PMCPMC11087457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.